Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute lymphoblastic leukemia (ALL). In this educational program, these experts discuss practical guidance on integrating T-cell therapies into clinical care, including challenges in treatment selection, sequencing, and toxicity management.
This educational activity is an archive of the live symposium held on February 26, 2026.
Target Audience
This activity is designed for hematologists, oncologists, transplant physicians, and advanced practice providers involved in the diagnosis and management of patients with ALL. Pharmacists, nurses, and other health care professionals engaged in the multidisciplinary care of patients receiving CAR T-cell therapy or bispecific antibody treatment will also benefit from this session.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial data on approved and emerging therapeutic strategies for ALL, with a focus on advances in bispecific antibodies and CAR T-cell therapies
- Interpret the latest guidelines and evidence for biomarker-driven strategies to stratify risk and guide the use of bispecific and CAR T-cell therapies in patients with ALL
- Describe best practices for mitigating and managing treatment-related adverse events in patients with ALL
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here